Canada is fast becoming a hub of biotech innovation.
In October 2016, Quark Venture Inc., a Vancouver-based venture capital firm, and China’s GF Securities announced a $500 million USD Global Health Sciences Venture Fund. This life sciences fund, the largest of its kind in Canada, is designed to invest in a diversified portfolio of innovative biotechnology and health sciences companies in Canada and around the world.
Established in 2015, Quark Venture Inc. is focused on equity financing of health sciences companies with breakthrough technology and platforms who are addressing unmet medical needs through innovations in drug development, medical devices, health IT and emerging convergent technologies. Quark Venture's strategic goal is to support and enable companies they invest in to grow, create value and be successful by providing not only financial support, but also developmental, infrastructure and expertise support, as needed, through their global network.
Quark Venture representatives Karimah Es Sabar, CEO, Zafria Avnur, CSO, and, Kaley Wilson, Director of Business Development, will be in attendance to present an overview of Quark Venture and the company's key areas of interest. Following the presentation, don't miss the opportunity to introduce yourself to Karimah, Zafria and Kaley during the networking lunch. And finally, for those companies who apply online and are approved, one-on-one meetings with Quark Venture will provide an intimate forum to discuss your company.
10:30 AM | Registration Opens and Networking
11:00 AM | Presentation and Q&A
11:45 AM | Networking Lunch
1:00-5:00 PM | One-on-one Meetings*
*Companies must have applied for a one-on-one meeting ahead of time and be approved. The application period ends on February 9th, 2017.
Quark Venture Participating Representatives:
Zafrira Avnur, Ph.D. | Chief Scientific Officer, Quark Venture Inc.- Boston, MA, USA
Zafrira Avnur, Ph.D., is Chief Scientific officer at Quark Venture and heads Quark Venture’s Boston office. Prior to joining Quark Venture in October 2016, she was the Global Head, Academic Collaborations, Roche Partnering. Zafrira holds a post doctorate (Cancer Biology) from Stanford University, and a Ph.D. from Weizmann Institute (cell Biology). She was based in Palo Alto, California, USA, from 1987 until 2006, in various positions in the Research and Development area at Roche. Amongst the positions she held are Distinguished Scientist in Roche Bioscience; Disease Area Head for Osteoporosis and Head of Dept. of Musculoskeletal Research. From 2006 she was based in Basel Switzerland. She held positions of Director of Scientific evaluation and Director of Biomarker Alliances. Dr. Avnur has published more than 30 peer-reviewed manuscripts and holds a number of patents.
Karimah Es Sabar | Chief Executive Officer & Partner, Quark Venture Inc. - Vancouver, British Columbia, Canada
Prior to joining Quark Venture, Karimah led the Centre for Drug Research and Development as President & CEO, and before that, Life Sciences BC. She has an expansive global career spanning multi-national pharmaceutical/biotechnology companies, start-ups, not-for-profit organizations and venture investment. Karimah has global experience, a large network, as well as leadership in marketing, business development, investment, strategic alliances, global collaborations and public private partnerships. She has raised significant funds, brought products to market, and has also developed and executed innovation and translation strategies in the life science sector and in biotech investment. Ms. Es Sabar, who has received multiple awards and recognitions for her pioneering work, holds an Executive Certificate in Management and Leadership from the MIT Sloan School of Management, a MSc degree in Neurochemistry from the Institute of Psychiatry ‒ University of London, England ‒ and a BSc Joint Honours degree in Biochemistry/Chemistry from the University of Salford in Manchester, England.
Kaley Wilson Ph.D. | Director, Business Development, Quark Venture, Inc.
In her previous role as Associate Director, Partnerships, at the Centre for Drug Research and Development (CDRD), Dr. Wilson worked in tandem with CDRD’s President and CEO and Executive Team playing a key role in building and maintaining the organization’s strategic alliances and partnerships with industry, academia, government, foundations and other organizations which were critical to CDRD realizing its vision of transforming the culture of scientific innovation and commercialization impacting human health. Dr. Wilson was also a key member of CDRD’s Project Search and Evaluation Team on which she lead the identification and evaluation of drug discovery projects with potential therapeutic value in the areas of infection, inflammation and immunity — her areas of scientific expertise. Dr. Wilson obtained her PhD at the University of British Columbia (UBC), Canada. During her Ph.D. Dr Wilson was the recipient of a number of prestigious scholarships and awards including the Doctoral Research Award, CIHR; Trainee Research Award, MSFHR and the PGS-A Scholarship, NSERC. Dr. Wilson was also the 2008 recipient of the Gattefosse Canada/Canadian Society for Pharmaceutical Sciences Research Award.
Presentation & Lunch
CA$ 25 | General Public
CA$ 15 | Academic
CA$ 40 | General Public Onsite
Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Pre-registration to attend the presentation, Q&A, and lunch will remain open until noon on March 6th (or sold out).
FREE | Application
FREE | Accepted Companies
Companies must have applied for a one-on-one meeting ahead of time. The one-on-one application period ends on February 9th, 2017. Your application will be reviewed and you will be notified of acceptance by email. Acceptance of one-on-one meetings is not guaranteed as all applications must be approved.
JLABS @ Toronto
MaRS Centre, West Tower
661 University Ave, Suite 1300 [13th Floor]
About the Meet with... Series:
The purpose of the Meet with Series events sponsored by JLABS is to help start-up entrepreneurs, as well as the academic community, connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started. Past participants include the Wellcome Trust, Bill & Melinda Gates Foundation, MedImmune Ventures, Mercury Fund, DARPA's Biological Technologies Office, Correlation Ventures, Breakout Labs, New Enterprise Associates, Canaan Partners, Thomas McNerney & Partners, NCI, NCATS, NINDS, Allegory Venture Partners, Clarus Ventures, Johnson & Johnson Innovation, California Institute for Regenerative Medicine, Astellas Venture Management, and OrbiMed.
Save This Event
When & Where
JLABS @ Toronto
JLABS, part of Johnson & Johnson Innovation, is a network of life science incubators providing emerging companies many of the advantages of being in a big company, without the capital investment. JLABS offers singular bench tops, modular wet lab units and office space on a short-term basis, allowing companies to pay only for the space they need, with an option to quickly expand when they have the resources to do so. Companies residing at JLABS also have access to core research labs hosting specialized capital equipment and shared administrative areas. JLABS is an open innovation model, and the agreement for space does not grant JLABS or Johnson & Johnson Innovation any stake or rights in the companies, nor will the companies have a guaranteed future affiliation with JLABS. The flagship facility is located in San Diego at Janssen's West Coast Research Center, and JLABS has now two established locations in San Francisco - one through a collaboration with the California Institute for Quantitative Biosciences (QB3) and a second standalone facility - one in Boston through a collaboration with Lab Central, one in Houston through a collaboration with TMC, and one in Toronto through a collaboration with MaRS. For more information please visit jlabs.jnjinnovation.com.